S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
S&P 500   2,626.65 (+3.35%)
DOW   22,327.48 (+3.19%)
QQQ   192.04 (+3.64%)
AAPL   254.81 (+2.85%)
FB   165.95 (+5.84%)
MSFT   160.23 (+7.03%)
GOOGL   1,146.31 (+3.25%)
AMZN   1,963.95 (+3.36%)
CGC   14.46 (-0.89%)
NVDA   265.59 (+5.09%)
BABA   191.27 (+1.42%)
MU   44.52 (+2.39%)
GE   7.89 (+3.54%)
TSLA   502.13 (-2.38%)
AMD   47.86 (+2.75%)
T   30.23 (+1.31%)
ACB   0.89 (-13.63%)
F   5.03 (-3.08%)
NFLX   370.96 (+3.88%)
BAC   22.04 (+2.04%)
GILD   75.93 (+4.23%)
PRI   90.71 (+0.83%)
DIS   99.80 (+3.53%)
Log in

NYSE:AMRX - Amneal Pharmaceuticals Stock Price, Forecast & News

$3.07
+0.07 (+2.33 %)
(As of 03/30/2020 04:00 PM ET)
Today's Range
$3.00
Now: $3.07
$3.24
50-Day Range
$2.46
MA: $3.99
$5.11
52-Week Range
$2.27
Now: $3.07
$14.65
Volume1.61 million shs
Average Volume1.86 million shs
Market Capitalization$918.62 million
P/E RatioN/A
Dividend YieldN/A
Beta1.68
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company has operations in the United States, Switzerland, India, Ireland, the United Kingdom and internationally. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.
Read More
Amneal Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone908-947-3120

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.63 billion
Cash Flow$1.15 per share
Book Value$1.16 per share

Profitability

Net Income$-361,920,000.00

Miscellaneous

Employees5,500
Market Cap$918.62 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive AMRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRX and its competitors with MarketBeat's FREE daily newsletter.


Amneal Pharmaceuticals (NYSE:AMRX) Frequently Asked Questions

How has Amneal Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Amneal Pharmaceuticals' stock was trading at $3.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AMRX stock has decreased by 5.5% and is now trading at $3.07. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amneal Pharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last year. There are currently 2 sell ratings, 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Amneal Pharmaceuticals.

When is Amneal Pharmaceuticals' next earnings date?

Amneal Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Amneal Pharmaceuticals.

How were Amneal Pharmaceuticals' earnings last quarter?

Amneal Pharmaceuticals Inc (NYSE:AMRX) released its earnings results on Wednesday, February, 26th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.05 by $0.03. The firm earned $397 million during the quarter, compared to the consensus estimate of $382.10 million. Amneal Pharmaceuticals had a negative net margin of 22.25% and a positive return on equity of 15.09%. The firm's revenue was down 20.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.33 EPS. View Amneal Pharmaceuticals' earnings history.

What guidance has Amneal Pharmaceuticals issued on next quarter's earnings?

Amneal Pharmaceuticals issued an update on its FY20 earnings guidance on Wednesday, February, 26th. The company provided earnings per share (EPS) guidance of 0.45-0.60 for the period, compared to the Thomson Reuters consensus estimate of $0.52. The company issued revenue guidance of 1.875-1.975 billion, compared to the consensus revenue estimate of $1.68 billion.

What price target have analysts set for AMRX?

11 brokers have issued 1-year target prices for Amneal Pharmaceuticals' shares. Their forecasts range from $2.50 to $14.00. On average, they expect Amneal Pharmaceuticals' share price to reach $6.30 in the next year. This suggests a possible upside of 105.2% from the stock's current price. View analysts' price targets for Amneal Pharmaceuticals.

Has Amneal Pharmaceuticals been receiving favorable news coverage?

Media coverage about AMRX stock has trended very negative recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amneal Pharmaceuticals earned a news sentiment score of -3.3 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutAmneal Pharmaceuticals.

Are investors shorting Amneal Pharmaceuticals?

Amneal Pharmaceuticals saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 4,390,000 shares, an increase of 20.3% from the February 13th total of 3,650,000 shares. Based on an average daily trading volume, of 2,670,000 shares, the short-interest ratio is presently 1.6 days. Currently, 4.9% of the shares of the stock are short sold. View Amneal Pharmaceuticals' Current Options Chain.

Who are some of Amneal Pharmaceuticals' key competitors?

What other stocks do shareholders of Amneal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Nektar Therapeutics (NKTR), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX), Canopy Growth (CGC), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Progenics Pharmaceuticals (PGNX) and NIO (NIO).

Who are Amneal Pharmaceuticals' key executives?

Amneal Pharmaceuticals' management team includes the following people:
  • Mr. Paul M. Bisaro, Exec. Chairman (Age 58)
  • Mr. Chirag K. Patel, Co-Founder & Co-Chairman (Age 52)
  • Mr. Chintu Patel, Co-Founder & Co-Chairman (Age 47)
  • Mr. Robert A. Stewart, Pres, CEO & Director (Age 51)
  • Ms. Nikita Shah, Sr. VP & Chief HR Officer (Age 41)

What is Amneal Pharmaceuticals' stock symbol?

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Who are Amneal Pharmaceuticals' major shareholders?

Amneal Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (0.76%), Geode Capital Management LLC (0.51%), Bank of New York Mellon Corp (0.44%), Norges Bank (0.36%), Prudential Financial Inc. (0.31%) and Mackay Shields LLC (0.26%). Company insiders that own Amneal Pharmaceuticals stock include Andrew S Boyer, Bryan M Reasons, Chintu Patel, Chirag K Patel, Gautam Patel, International Ltd Fosun, Joseph Todisco, Nikita Shah, Paul Bisaro, Paul M Meister, Peter R Terreri, Pradeep Bhadauria and Ted C Nark. View institutional ownership trends for Amneal Pharmaceuticals.

Which institutional investors are selling Amneal Pharmaceuticals stock?

AMRX stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Spark Investment Management LLC, Strs Ohio, First Trust Advisors LP, Cubist Systematic Strategies LLC, Goldman Sachs Group Inc., UBS Asset Management Americas Inc., and Meeder Asset Management Inc.. View insider buying and selling activity for Amneal Pharmaceuticals.

Which institutional investors are buying Amneal Pharmaceuticals stock?

AMRX stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Bank of New York Mellon Corp, Mackay Shields LLC, Marshall Wace LLP, Bank of America Corp DE, State Street Corp, Nuveen Asset Management LLC, and Geode Capital Management LLC. Company insiders that have bought Amneal Pharmaceuticals stock in the last two years include Andrew S Boyer, Chintu Patel, Chirag K Patel, Gautam Patel, International Ltd Fosun, Joseph Todisco, Paul Bisaro, Paul M Meister, Pradeep Bhadauria, and Ted C Nark. View insider buying and selling activity for Amneal Pharmaceuticals.

How do I buy shares of Amneal Pharmaceuticals?

Shares of AMRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amneal Pharmaceuticals' stock price today?

One share of AMRX stock can currently be purchased for approximately $3.07.

How big of a company is Amneal Pharmaceuticals?

Amneal Pharmaceuticals has a market capitalization of $918.62 million and generates $1.63 billion in revenue each year. The company earns $-361,920,000.00 in net income (profit) each year or $0.27 on an earnings per share basis. Amneal Pharmaceuticals employs 5,500 workers across the globe. View additional information about Amneal Pharmaceuticals.

What is Amneal Pharmaceuticals' official website?

The official website for Amneal Pharmaceuticals is http://www.amneal.com/.

How can I contact Amneal Pharmaceuticals?

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-947-3120 or via email at [email protected]


MarketBeat Community Rating for Amneal Pharmaceuticals (NYSE AMRX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  313 (Vote Outperform)
Underperform Votes:  386 (Vote Underperform)
Total Votes:  699
MarketBeat's community ratings are surveys of what our community members think about Amneal Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel